Time: 7:54

Prima BioMed confirms trial recruitment

Prima BioMed (ASX:PRR) has announced the second cohort comprising six patients has now been fully recruited for its TACTI-mel (Two ACTive Immunotherapeutics in melanoma) clinical trial being conducted in Australia.

Patients with unresectable or metastatic melanoma that have had a suboptimal response to MSD’s PBS-listed KEYTRUDA were dosed with the higher 6 mg dose of IMP321 in combination with KEYTRUDA.

IMP321 is a first-in-class Antigen Presenting Cell (APC) activator based on the immune checkpoint LAG-3. As an APC activator, IMP321 boosts the network of dendritic cells in the body that can respond to tumour antigens for a better anti-tumour CD8 T cell response.